A phase I clinical study of immune cell therapy with MAGE-A4- or Survivin-specific Th1 cells for patients with refractory virulent tumors.

Trial Profile

A phase I clinical study of immune cell therapy with MAGE-A4- or Survivin-specific Th1 cells for patients with refractory virulent tumors.

Completed
Phase of Trial: Phase I

Latest Information Update: 13 May 2016

At a glance

  • Drugs CHP-MAGE-A4 (Primary)
  • Indications Cancer; Malignant melanoma
  • Focus Adverse reactions
  • Most Recent Events

    • 09 Oct 2013 Status changed from recruiting to completed as reported by University Hospital Medical Information Network - Japan.
    • 07 Jan 2012 Status changed from suspended to recruiting as reported by University Hospital Medical Information Network - Japan.
    • 16 Sep 2011 Status changed from recruiting to suspended as reported by University Hospital Medical Information Network - Japan.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top